The ascendancy of Viagra and its effect on the medicinal landscape presents a complex question for shareholders. While the first sales data were astounding, the intellectual property has lapsed, leading to a deluge of copycat alternatives that are eroding profit. In addition, the industry is facing challenges related to demographic trends and shift